Roy S. Herbst, MD, PhD
Advertisement
Articles by Roy S. Herbst, MD, PhD
Advertisement
Latest Updated Articles
Dr. Herbst on Biomarkers for Immunotherapy Response in NSCLCPublished: December 16th 2020 | Updated:
Dr Herbst on Adjuvant Osimertinib in EGFR-mutant NSCLCPublished: June 4th 2023 | Updated:
Dr. Herbst on the Approval of Adjuvant Osimertinib in EGFR+ NSCLCPublished: January 6th 2021 | Updated:
Dr. Herbst on Advances of Immunotherapy in Lung CancerPublished: October 14th 2016 | Updated:
Dr. Herbst on the Impact of Frontline Immunotherapy in Lung CancerPublished: January 7th 2017 | Updated:
Dr. Herbst on Combination Therapies for Lung CancerPublished: January 20th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5